Sector News

No sale for Novartis' $14B Roche stake, but the revamp's not done

October 13, 2017
Life sciences

Novartis has decided to put its $14 billion Roche stake back on the closet shelf. After more than a year of running numbers and taking the market’s temperature—while playing out its own company business—Novartis has decided to hang onto its one-third interest in the rival drugmaker.

That’s the word from Chairman Joerg Reinhardt, who told the Swiss publication Handelszeitung Wednesday that Novartis won’t be offloading its Roche shares after all. “We said at that time that we would consider whether it would be useful to sell,” Reinhardt said in an interview with the paper. “We then concluded that this is not the case.”

Novartis had tabbed the investment for potential sale as part of a strategic review that has, over the last several years, reshaped the company—and is likely to continue next year as the company’s new CEO, Vas Narasimhan, moves to the helm from his current post as R&D chief.

Unloading the Roche shares could have raised anywhere from $12 billion to more than $14 billion, analysts figured, and would have supplied some funds for M&A.

Since 2014, the Swiss drugmaker has traded off most of its vaccines to GlaxoSmithKline in return for the British drugmaker’s oncology drugs, and sold its flu-shot stable to Seqirus. Animal health sold to Eli Lilly. And its consumer health business went into a joint venture run by GSK.

Narasimhan, a Harvard-trained doctor and public health specialist, has so far only said he’s intent on driving innovation; he made his debut as forthcoming CEO just as Novartis won early approval for its CAR-T cell therapy Kymriah, the first in an entirely new wave of treatments for cancer. Getting that $475,000 therapy onto the market will be a challenge of its own, and the company faces others, too, including the ongoing rollout of the heart failure drug Entresto and the generic pricing pressure that’s shrinking sales at the company’s generics unit, Sandoz.

How M&A fits into all of that remains to be seen, but the Roche shares aren’t the only assets Novartis could hive off for cash, of course. Other streamlining options? The Swiss drugmaker was said to be shopping a $496 million portfolio of central nervous system meds late last year, and this spring, word was that it was considering selling off some respiratory drug rights.

And then there’s the eye unit Alcon, which has been under internal scrutiny for a while as its sales floundered. Hiving off that business—through a sale or spinoff—could raise $25 billion to $35 billion, and outgoing CEO Joe Jimenez has said he’ll update investors on that possibility by the end of this year. Or consumer health: Novartis could sell its stake in the GSK venture and bring in some $10 billion in the process.

Meanwhile, Novartis is said to be eyeing a deal for the radiotherapy developer Advanced Accelerator Applications, a maker of radioactive tracers used in diagnostic scans. AAA’s lead pipeline candidate, Lutathera, is an actual cancer therapeutic in a field Novartis already knows: neuroendocrine tumors (NETs). If it comes through, the deal would be “highly synergistic” with the company’s existing NET franchise, which includes Sandostatin and Afinitor, Canaccord Genuity analyst John Newman said last month.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).